Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.
Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.
Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.
Price: 16.06, Change: -0.15, Percent Change: -0.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments